About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Topical PDE-4 Inhibitor for Chronic Plaque Psoriasis Effective in Phase 2b Trial

by Iswarya on July 16, 2020 at 11:30 AM
Font : A-A+

Topical PDE-4 Inhibitor for Chronic Plaque Psoriasis Effective in Phase 2b Trial

Topical roflumilast, a potent, selective topical phosphodiesterase-4 inhibitor, showed marked improvement in patients with chronic plaque psoriasis, including challenging lesions in tough-to-treat intertriginous areas in a phase 2b, randomized, double-blind, vehicle-controlled clinical trial, reports a new study. The findings of the study are published in The New England Journal of Medicine.

According to Mark Lebwohl, MD, Waldman Professor and Chair of Dermatology at the Icahn School of Medicine at Mount Sinai, and lead investigator of the study, the results are particularly encouraging for patients who need new and better options to treat this chronic skin disease.

Advertisement


"Effectively treating psoriasis with topical therapies, which the vast majority of patients receive, is especially challenging due to side effects, tolerability, or efficacy of existing topical treatments. Roflumilast cream could really be a game-changer."

Roflumilast which contains PDE4, an intracellular enzyme that regulates pro-inflammatory and anti-inflammatory cytokine production and cell proliferation has been implicated in a wide range of inflammatory diseases and approved by the U.S. Food and Drug Administration for the treatment of chronic obstructive pulmonary disease (COPD) in 2011.
Advertisement

In the double-blinded trial, a total of 331 adults with plaque psoriasis were randomly assigned in a 1:1:1 ratio to receive topical treatment with roflumilast cream 0.3%, 0.15%, or matching treatment applied once daily for 12 weeks. A total of 109 patients were treated with roflumilast cream 0.3%, 113 with 0.15% cream, and 109 with the matching treatment. The primary efficacy outcome was global investigator assessment (IGA, a five-item scale assessing plaque thickening, scaling, and erythema, ranging from 0, clear, to 4, severe) of clear or almost clear at week six. Secondary outcomes included clear or almost clear plus a two-grade improvement (IGA success), IGA success on an intertriginous IGA, and change in psoriasis area and severity index (PASI).

Psoriasis is an immune disease that occurs in about two percent of adults in Western countries. About 90 percent of psoriasis cases are plaque psoriasis, which is characterized by "plaques" or raised red areas of skin covered with a silver or white layer of scale. Psoriatic plaques can appear on any area of the body, but most often appear on the scalp, knees, elbows, trunk, and limbs, and the plaques are often itchy and sometimes painful. Plaques in certain anatomical areas present particular treatment challenges, including the face, elbows, knees, scalp, and other areas of the skin that may touch or rub together.

"The results from this phase 2b study data provide further evidence of the potential of roflumilast cream as a once-daily treatment for patients with plaque psoriasis who currently lack suitable treatment options," said Howard Welgus, MD, Chief Medical Officer at Arcutis, the biopharmaceutical company, which funded and co-authored the study. "We are pleased to share these results, which suggest topical roflumilast was well tolerated and efficacious, with the broader scientific community."

Mount Sinai is currently conducting phase 3 clinical studies with the drug.

Source: Newswise
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Black Tea Protects against Blood Pressure and Heart Diseases
Green Mediterranean Diet may Help Repair Age-Related Brain Damages
Cervical Cancer Awareness Month 2022
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Psoriasis Dry Skin Symptom Evaluation Foods that are Bad for your Skin Itchy Scalp Peyronie´s Disease Diet for Psoriasis Scalp Psoriasis Psoriasis Cure with Homeopathy: Fact or Fiction Psoriatic Arthritis 

Recommended Reading
Nail Psoriasis
Psoriasis is an autoimmune disease, which in rare cases can, also affect the nails, making them ......
Psoriasis Cure with Homeopathy: Fact or Fiction
Psoriasis, a chronic autoimmune skin disease has phases of exaggeration and remission. Homeopathic ....
Scalp Psoriasis
Scalp psoriasis, a common skin disorder causes lesions on the scalp. There is no cure for scalp ......
Psoriasis Therapy can Reduce Coronary Inflammation
Psoriasis therapy can reduce coronary inflammation, thereby lowering the risk of cardiac events. ......
Diet for Psoriasis
Learn what causes psoriasis, the appropriate diet to follow and the importance of diet in the treatm...
Dry Skin Symptom Evaluation
Dry skin a result in inadequate hydration of the skin. This could be either due to a reduced intake...
Foods that are Bad for your Skin
Hydration, sebum formation and skin acidity determine the skin condition. Along with aging and envir...
Peyronie´s Disease
Peyronie''s disease is caused by scar tissue along the length of the penis, which causes the penis t...
Psoriasis
Psoriasis is a recurrent and complex inflammatory skin disorder that can have tremendous physical an...
Psoriatic Arthritis
Psoriatic arthritis is a kind of autoimmune inflammatory arthritis, which develops in 30 percent of ...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
CONSULT A DOCTOR
I have read and I do accept terms of use - Telemedicine

Advantage Medindia: FREE subscription for 'Personalised Health & Wellness website with consultation' (Value Rs.300/-)